Synthesis and structure-activity relationships of 6-phenylaliphatic- substituted C19 steroids having a 1,4-diene, 4,6-diene, or 1,4,6-triene structure as aromatase inhibitors

Steroids

Volumn 64, Issue 3, 1999, Pages 187-196

  Numazawa, M ^a   Yamaguchi, S ^a  

^a TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

6 Phenylaliphatic substituent; Androstenedione analog; Aromatase; Inhibitor; Suicide substrate

Indexed keywords

6 BENZYLANDROSTA 4,6 DIENE 3,17 DIONE; 6 PHENETHYLANDROSTA 4,6 DIENE 3,17 DIONE; ANDROSTA 1,4 DIENE 3,17 DIONE DERIVATIVE; ANDROSTA 1,4,6 TRIENE 3,17 DIONE DERIVATIVE; ANDROSTA 4,6 DIENE 3,17 DIONE DERIVATIVE; ANDROSTENEDIONE DERIVATIVE; AROMATASE; AROMATASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; MICROSOME; PLACENTA; STEROIDOGENESIS; STRUCTURE ACTIVITY RELATION;

AROMATASE INHIBITORS; ENZYME INHIBITORS; HUMANS; MICROSOMES; PLACENTA; STEROIDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032979982     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-128X(98)00088-9     Document Type: Article

References (40)

1. Thompson EA Jr, Siiteri PK. The involvement of human placental microsomal cytochrome P-450 in aromatization. J Biol Chem 1974; 249:5373-8.
2. Kellis J Jr, Vickery LE. Purification and characterization of human placental aromatase cytochrome P-450. J Biol Chem 1987;262:4413-20.
3. Yoshida N, Osawa Y. Purification of human placental aromatase cytochrome P-450 with monoclonal antibody and its characterization. Biochemistry 1991;30:3003-10.
4. Meyer AS. Conversion of 19-hydroxy-4-androstene-3,17-dione to estrone by endocrine tissue. Biochim Biophys Acta 1995;17:441-2.
5. Arigoni D, Battaglia R, Akhtar M, Smith T. Stereospecificity of oxidation at C-19 in oestrogen biosynthesis. J Chem Soc Chem Commun 1975:185-7.
6. 1H]-3β-hydroxy- androst-5-en-17-one by human placental aromatase. J Am Chem Soc 1986;108:1847-52.
7. Akhtar M, Calder MR, Corina DL, Wright JN. Mechanistic studies on C-19 demethylation in oestrogen biosynthesis. Biochem J 1982;201: 569-80.
8. 2. J Chem Soc Chem Commun 1976:854-6.
9. Bednarski PJ, Nelson SD. Dissociation of 19-hydroxy-, 19-oxo-, and aromatizing activities in human placental microsomes through the use of suicide substrate to aromatase. J Steroid Biochem 1989;32:309-16.
10. 18 steroids. Biochemistry 1968;7:33-40.
11. 2H]-androgens into oestrogens by human placental aromatase. Biochem J 1990;268: 553-61.
12. Brodie AMH, Schwarzel WC, Shaikh AA, Brodie HJ. The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen dependent progress in reproduction and breast cancer. Endocrinology 1977;100:1684-95.
13. Hervey HA, Lipton A, Santen RJ. Aromatase: new perspectives for breast cancer. Cancer Res 1982;42(Suppl.):3261s-9s.
14. Henderson D. Aromatase inhibitors: their biochemistry and clinical potential. J Steroid Biochem 1987;27:905-14.
15. Covey DF. Aromatase inhibitors: specific inhibitors of oestrogen biosynthesis. In: Berg D, Plemel M, editors. Steroid Biosynthesis Inhibitors: Pharmaceutical and Agrochemical Aspects. Chichester, England: Ellis Horwood Ltd., 1988, pp. 534-71.
16. Banting L, Nicholls PJ, Shaw MA, Smith HJ. Recent developments in aromatase inhibition as a potential treatment of estrogen-dependent breast cancer. In: Ellis GP, West GB, editors. Progress in Medicinal Chemistry, Vol 26. Amsterdam, The Netherlands: Elsevier Science Publishers, B.W., 1989. pp. 253-98.
17. Bossche HV. Inhibitors of P-450-dependent steroid biosynthesis: from research to medical treatment. J Steroid Biochem Mol Biol 1992;43:1003-21.
18. Brodie AMH, Santen RJ. Aromatase and its inhibitors in breast cancer treatment-overview and perspective. Breast Cancer Res Treat 1994;30:1-6.
19. Covey DF, Hood WF. A new hypothesis based on suicide inhibitor studies for the mechanism of action of aromatase. Cancer Res 1982; 42(Suppl.):3327s-33s.
20. Schwarzel WC, Kruggel WG, Brodie HJ. Studies on the mechanism of estrogen biosynthesis. VIII. The development of inhibitors of the enzyme system in human placenta. Endocrinology 1973;92:866-80.
21. Covey DF, Hood WF. Enzyme-generated intermediates derived from 4-androstene-3,6,17-trione and 1,4,6-androstatriene-3,17-dione cause a time-dependent decrease in human placental aromatase activity. Endocrinology 1981;108:1597-9.
22. Henderson D, Norbirath G, Kerb U. 1-Methyl-1,4-androstadiene-3,17-dione (SH 489): characterization of an irreversible inhibitor of estrogen biosynthesis. J Steroid Biochem 1986;24:303-6.
23. Giudici D, Ornati G, Briatico G, Buzzetti F, Lombardi P, Di Salle E. 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a New Irreversible aromatase inhibitor. J Steroid Biochem 1988;30:391-4.
24. 19 steroid. J Biol Chem 1987;262: 8685-9.
25. Ebrahimian S, Chen H-H, Brueggemeier RW. Synthesis and biochemical studies of 7α-substituted androsta-1,4-diene-3,17-dione as enzyme-activated irreversible inhibitors of aromatase. Steroids 1993; 58:414-22.
26. Sherwin PF, McMullan PC, Covey DF. Effects of steroid D-ring modification on suicide inactivation and competitive inhibition of aromatase by analogues of androsta-1,4-diene-3,17-dione. J Med Chem 1989;32:651-8.
27. Marsh DA, Brodie HJ, Garret W, Tsai-Morris C-H, Brodie AMH. Aromatase inhibitors synthesis and biological activity of androstenedione derivatives. J Med Chem 1985;28:788-95.
28. Di Salle E, Giudici D, Ornati G, Briatico G, D'Alessio R, Villa V, Lombardi P. 4-Aminoandrostenedione derivatives: A novel class of irreversible aromatase inhibitors. Comparison with FCE 24304 and 4-hydroxyandrostenedione. J Steroid Biochem Mol Biol 1990;37: 369-74.
29. Li P-K, Brueggemeier W. Synthesis and biochemical studies of 7-substituted 1,4,6-androstatriene-3,17-diones as aromatase inhibitors. J Med Chem 1990;33:101-5.
30. Li P-K, Brueggemeier RW. 7-Substituted 1,4,6-androstatriene-3,17-diones as enzyme-activated irreversible inhibitors of aromatase. J Steroid Biochem 1990;36:533-9.
31. Numazawa M, Oshibe M. 6-Alkyl- and 6-aryl-androst-4-ene-3,17-diones as aromatase inhibitors. Synthesis and structure-activity relationships. J Med Chem 1994;37:1312-9.
32. Numazawa M, Oshibe M. Further studies on 6-alkylandrost-4-ene-3,17-diones as aromatase inhibitors: elongation of the 6-alkyl chain. Steroids 1995;60:506-11.
33. Numazawa M, Oshibe M, Yamaguchi S, Tachibana M. Time-dependent inactivation of aromatase by 6-alkylandrosta-1,4-diene-3,17-diones. Effects of length and configuration of the 6-alkyl group. J Med Chem 1996;39:1033-8.
34. Numazawa M, Oshibe M, Yamaguchi S. 6-Alkylandrosta-4,6-diene-3,17-diones and their 1,4,6-triene analogs as aromatase inhibitors. Steroids 1997;62:595-602.
35. Numazawa M, Yamaguchi S. 6-Phenylaliphatic-substituted androst-4-ene-3,17-diones as aromatase inhibitors. Structure-activity relationships. J Steroid Biochem Mol Biol 1998;67:41-8.
36. Vida JA, Gut M. Steroid homolog containing a pyrazole nucleus. J Med Chem 1963;6:792-3.
37. Ryan KJ. Biological aromatization of steroids. J Biol Chem 1959; 234:268-72.
38. Siiteri PK, Thompson EA. Human placental aromatase. J Steroid Biochem 1975;6:317-22.
39. Numazawa M, Mutsumi A, Hoshi K, Oshibe M, Ishikawa E, Kigawa H. Synthesis and biochemical studies of 16- or 19-substituted androst-4-enes as aromatase inhibitors. J Med Chem 1991;34:2496-504.
40. Kitz R, Wilson IB. Effects of metanesulfonic acid as irreversible inhibitors of acetylcholine esterase. J Biol Chem 1962;237:3245-9.